ALEXANDRIA, Va. / Nov 16, 2023 / Business Wire / Spok Holdings, Inc. (NASDAQ: SPOK), a global leader in healthcare communications, today announced that Vincent D. Kelly, chief executive officer, will participate in the 35th annual Piper Sandler & Co. healthcare conference on November 29, 2023 in New York. The Company’s presentation is scheduled for 12:30 pm ET. Spok will also host a series of 1X1 meetings with investors on November 29, 2023.
The presentation will also be webcast and can be accessed via the conference presentation link, and in the investor relations section of the Company's website: http://www.spok.com.
About Spok
Spok, Inc., a wholly owned subsidiary of Spok Holdings, Inc. (NASDAQ: SPOK), headquartered in Alexandria, Virginia, is proud to be a global leader in healthcare communications. We deliver clinical information to care teams when and where it matters most to improve patient outcomes. Top hospitals rely on the Spok Care Connect® platform to enhance workflows for clinicians and support administrative compliance. Our customers send over 70 million messages each month through their Spok® solutions. Spok enables smarter, faster clinical communication. For more information, visit spok.com.
Spok is a trademark of Spok Holdings, Inc. Spok Care Connect and Spok Mobile are trademarks of Spok, Inc.
Last Trade: | US$16.01 |
Daily Change: | 0.02 0.13 |
Daily Volume: | 49,533 |
Market Cap: | US$324.520M |
October 30, 2024 July 24, 2024 May 01, 2024 March 07, 2024 February 21, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load